Genentech (Roche) Deal History & Licensing Activity
Genentech (Roche) is a large pharma headquartered in Switzerland. Over the past three years, Genentech (Roche) has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
Genentech (Roche) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Genentech (Roche) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| IL-15 cytokine therapeutics | Genentech | Other | Unknown | co development | Jul 3, 2026 |
| XmAb24306 (IL-15 cytokine) | Genentech | Antibodies | Unknown | option | Jun 30, 2026 |
Genentech (Roche) Pipeline Focus
Therapeutic areas and modalities where Genentech (Roche) is most active based on deal history and clinical trial data.
Therapeutic Areas
Genentech (Roche) Clinical Pipeline
Genentech (Roche) has 50 active clinical trials across 6 development phases.
5
Not Applicable
5
Unknown
1
Phase 4
9
Phase 1
19
Phase 2
11
Phase 3
See How Your Asset Matches Genentech (Roche)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Genentech (Roche) Licensing & Deal Activity
Genentech (Roche) is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Genentech (Roche) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genentech (Roche) include Solid Tumors (13 deals and trials), CNS Disorders (6 deals and trials), Metabolic (6 deals and trials), and Autoimmune (6 deals and trials). In terms of modality, Genentech (Roche) has shown particular interest in other, antibodies, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genentech (Roche) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Genentech (Roche)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.